Literature DB >> 17223318

Is all free time above the minimum inhibitory concentration the same: implications for beta-lactam in vivo modelling.

C Andrew DeRyke1, David P Nicolau.   

Abstract

Previously, ertapenem 50 mg/kg every 6h given subcutaneously to mice achieved a similar 24-h cumulative free time above the minimum inhibitory concentration (fT>MIC) to 1g every 24h in humans. However, this simplified regimen (SR) does not provide a superimposable concentration-time profile to that observed in humans, thus allowing concentrations to fluctuate above and below the minimum inhibitory concentration (MIC) throughout the 24-h period. Herein, we compared a complex regimen (CR; 9 various mg/kg doses over 24 h) providing a near superimposable concentration-time profile with the SR to determine implications on bacterial kill against eight extended-spectrum beta-lactamase (ESBL)-producing isolates over a wide MIC range. The CR resulted in a similar (+/-5%) 24-h cumulative fT>MIC to ertapenem 1 g every 24h in humans over an MIC range of 0.032 mg/L to 16 mg/L. Similar bacterial kill was observed with both regimens against all eight ESBL-producing isolates examined. In mouse models, it appears that the 24-h cumulative fT>MIC and not the distribution of the fT>MIC over 24 h drives efficacy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17223318     DOI: 10.1016/j.ijantimicag.2006.10.006

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  8 in total

1.  Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors:  Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Efficacy of human-simulated exposures of tomopenem (formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection.

Authors:  Kiyoshi Sugihara; Kazuhiro Tateda; Naotoshi Yamamura; Tetsufumi Koga; Chika Sugihara; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

3.  Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants.

Authors:  Zhong-Ren Shi; Xing-Kai Chen; Li-Yuan Tian; Ya-Kun Wang; Gu-Ying Zhang; Lei Dong; Totsapol Jirasomprasert; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

4.  Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.

Authors:  C Andrew DeRyke; Mary Anne Banevicius; Hong Wei Fan; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

5.  Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.

Authors:  Amira A Bhalodi; Jared L Crandon; Donald Biek; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

6.  Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model.

Authors:  Dora E Wiskirchen; Patrice Nordmann; Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

7.  Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.

Authors:  John S Bradley; Jon Armstrong; Antonio Arrieta; Raafat Bishai; Shampa Das; Shirley Delair; Timi Edeki; William C Holmes; Jianguo Li; Kathryn S Moffett; Deepa Mukundan; Norma Perez; José R Romero; David Speicher; Janice E Sullivan; Diansong Zhou
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282.

Authors:  John O'Donnell; Angela Tanudra; April Chen; Daniel Hines; Ruben Tommasi; John Mueller
Journal:  ACS Infect Dis       Date:  2020-05-14       Impact factor: 5.084

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.